| Ms Debbie K Chirikos, MSW, LCSW | |
|
10075 N River Rd, Algonquin, IL 60102-9685 | |
| (847) 770-3484 | |
| (847) 658-3446 |
| Full Name | Ms Debbie K Chirikos |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 10075 N River Rd, Algonquin, Illinois |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275584153 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 149.011586 (Illinois) | Primary |
| Entity Name | Rockford Psychiatric Medical Services Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821391442 PECOS PAC ID: 6901089515 Enrollment ID: O20110318000777 |
News Archive
Novo Nordisk today presented phase 2 proof-of-concept data for its investigational insulin degludec, an ultra-long-acting basal insulin, which demonstrated the potential to help achieve target glycemic control when used once daily or three times weekly. These data were presented at the 70th Scientific Sessions of the American Diabetes Association.
Johns Hopkins investigators are testing a way to use drugs that target a cholesterol pathway to enhance the cancer-killing potential of standard chemotherapy drugs. Their tests, in mouse models of pancreatic cancer, may yield new and more effective combinations of current and possibly new anti-cancer drugs.
An experimental vaccine prevents the SARS virus from replicating in laboratory mice, according to a new report in the April 1 issue of Nature. Scientists at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, developed the vaccine. The vaccine was tested in a mouse model of SARS infection recently validated by other NIAID investigators.
Moderate to high levels of regular physical activity are associated with lower lung function decline among smokers and help to moderate their risk of developing chronic obstructive pulmonary disease (COPD), according to a large retrospective cohort study.
The new synthetic drug nicknamed Oz is set to become the major weapon in the fight against multi-drug resistant malaria and could be available to patients within three years.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Debbie K Chirikos, MSW, LCSW Po Box 188, Barrington, IL 60011-0188 Ph: (847) 770-3484 | Ms Debbie K Chirikos, MSW, LCSW 10075 N River Rd, Algonquin, IL 60102-9685 Ph: (847) 770-3484 |
News Archive
Novo Nordisk today presented phase 2 proof-of-concept data for its investigational insulin degludec, an ultra-long-acting basal insulin, which demonstrated the potential to help achieve target glycemic control when used once daily or three times weekly. These data were presented at the 70th Scientific Sessions of the American Diabetes Association.
Johns Hopkins investigators are testing a way to use drugs that target a cholesterol pathway to enhance the cancer-killing potential of standard chemotherapy drugs. Their tests, in mouse models of pancreatic cancer, may yield new and more effective combinations of current and possibly new anti-cancer drugs.
An experimental vaccine prevents the SARS virus from replicating in laboratory mice, according to a new report in the April 1 issue of Nature. Scientists at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, developed the vaccine. The vaccine was tested in a mouse model of SARS infection recently validated by other NIAID investigators.
Moderate to high levels of regular physical activity are associated with lower lung function decline among smokers and help to moderate their risk of developing chronic obstructive pulmonary disease (COPD), according to a large retrospective cohort study.
The new synthetic drug nicknamed Oz is set to become the major weapon in the fight against multi-drug resistant malaria and could be available to patients within three years.
› Verified 6 days ago
Senait Gebretsadik, Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 215 N Main St, Algonquin, IL 60102 Phone: 224-678-9033 Fax: 224-678-9493 | |
Mrs. Melissa Ann Prusha, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 3660 White Deer Dr, Algonquin, IL 60102 Phone: 847-863-1844 Fax: 847-458-2663 | |
James Kondrat, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 215 N Main St, Algonquin, IL 60102 Phone: 224-678-9033 Fax: 224-679-9493 | |
David Durpetti, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1138 N Main St, Algonquin, IL 60102 Phone: 847-658-4224 | |
Jill Middle Queffelec, L.C.S.W. Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2401 Harnish Dr, Algonquin, IL 60102 Phone: 630-926-7659 | |
Ms. Danae Ganos, MSW, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 275 Stonegate Rd, Unit K, Algonquin, IL 60102 Phone: 847-791-5514 Fax: 815-356-6445 |